Atorvastatin tab p / 20 mg film about 30 pieces of ozone


Atorvastatin tab p / 20 mg film about 30 pieces of ozone



Active substance:
1 tablet contains: in terms of atorvastatin – 10, 20,40 or 80 mg.
Product form:
Tablets, film-coated 10 mg, 20 mg, 40 mg and 80 mg. 10, 30 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 90 or 100 tablets per plastic cans or jars made of polyethylene terephthalate. One jar or 1, 2, 3, 4, 9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Hypersensitivity to any component of the drug. Active liver disease or increased activity “liver” transaminases in the blood plasma of unclear origin by more than 3-fold compared with the upper limit of normal (ULN). Age 18 years (insufficient clinical data on the efficacy and safety of the drug in this age group). Use in women of reproductive age who do not use adequate contraceptive methods. Pregnancy, lactation. Lactose intolerance, lactase deficiency, a syndrome of glucose-galactose malabsorption.
20 mg
• primary hypercholesterolemia (heterozygous familial and non-family hypercholesterolemia (type IIa Fredrickson classification); • combined (mixed) hyperlipidaemia (type IIa and IIb Fredrickson classification); • disbetalipoproteinemiya (type III Fredrickson classification) (as a supplement to the hypolipidemic diet) ; • familial endogenous hypertriglyceridemia (type IV classification Fredrickson), resistant to hypolipidemic diet; • homozygous familial hypercholesterolemia in low effektivnostidieto erapii and other non-pharmacological treatments; • primary prevention of cardiovascular events in patients without clinical evidence of coronary heart disease but with multiple risk factors for its development: age over 55 years, nicotine addiction, hypertension, diabetes, low levels of HDL-C plasma, genetic predisposition, including the background of dyslipidemia; • secondary prevention of cardiovascular events in patients with coronary heart disease with the aim of reducing Nia summary measure of mortality, myocardial infarction, stroke, rehospitalization for angina and the need for revascularization procedures.
pharmachologic effect
Pharmacological group:
Lipid-lowering agents – an inhibitor of GM G-CoA reductase. ATC code S10AA05.
Pharmacological properties:
A synthetic lipid-lowering agent. -Selective Atorvastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), klyuchevogofermenta converting 3-hydroxy-3-methylglutaryl-CoA to mevalonate – a precursor of sterols, including cholesterol. In patients with homozygous and heterozygous familial hypercholesterolemia, non-family forms of hypercholesterolemia, and mixed dyslipidemia, atorvastatin decreases the concentration of total cholesterol serum (CS), low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo-B), and lipoprotein cholesterol is very low density (VLDL-cholesterol) and triglycerides (TG) causes unstable increase (HDL-C) concentrations of high density lipoprotein. Atorvastatin decreases the concentration of cholesterol in blood plasma lipoproteins by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of “liver” LDL receptors on the cell surface, which leads to increased trapping and catabolism of LDL-C. Atorvastatin reduces the formation of LDL-C and the number of LDL particles, causes a marked and sustained increase in the activity of LDL-receptors in combination with favorable qualitative changes in LDL particles, but also reduces the concentration of LDL-C in patients with homozygous hereditary familial hypercholesterolemia resistant to therapy other hypolipidemic means. Atorvastatin in doses ranging from 10 mg to 80 mg reduces the concentration of total cholesterol by 30-46%, LDL-cholesterol – by 41-61%, Apo-B – by 34-50% and TG – by 14-33%. The results of therapy are similar in patients with heterozygous familial hypercholesterolemia, non-family forms of hypercholesterolemia, and mixed hyperlipidaemia, including patients with type 2 diabetes. In patients with isolated hypertriglyceridemia, atorvastatin reduces the concentration of total cholesterol, LDL-C, VLDL-cholesterol, Apo-B, and TG, and increases the concentration of HDL-C. Patients with disbetalipoproteinemiey atorvastatin reduces the concentration of cholesterol intermediate density lipoproteins. In patients with hyperlipoproteinemia type IIa and IIb according to Fredrickson mean value of increasing the concentration of HDL-C in the treatment of atorvastatin (10-80 mg) compared to baseline it is 5,1-8,7% and is independent of dose. There is a significant dose-dependent reduction in the magnitude relations: total cholesterol / HDL-cholesterol and LDL-C / HDL-cholesterol 29-44% and 37-55%, respectively. Atorvastatin 80 mg significantly reduced the risk of ischemic complications and mortality rate by 16% after 16 weeks of treatment, and the risk of re-hospitalization for angina, accompanied by signs of myocardial ischemia by 26%. In patients with different initial concentrations of LDL-C atorvastatin causes a reduction in the risk of ischemic events and death (in patients with myocardial infarction without Q-wave MI and unstable angina, as well as men and women, and in patients younger than 65 years of age and older). Reducing the concentration of LDL-C in the blood plasma correlates better with a dose of the drug than with its concentration in the blood plasma. The dose is selected taking into account therapeutic effects (see. The section “Method of administration and dose”). The therapeutic effect is achieved within 2 weeks after initiation of therapy, reaching a peak at 4 weeks and maintained throughout the treatment period. Atorvastatin 10 mg reduce fatal and nonfatal outcome of coronary heart disease (CHD) compared to placebo in hypertensive patients with three or more risk factors.
Conditions of supply of pharmacies
Dosing and Administration
Inside. Taken at any time of the day regardless of the meal. Before the start of treatment should be to try to get control of hypercholesterolemia with diet, exercise and weight loss in obese patients, as well as treatment of the underlying disease. In appointing the drug to the patient should be advised to standard hypocholesterolemic diet, which he must adhere to throughout the treatment period. The dose ranges from 10 mg to 80 mg 1 time per day and titrated with the initial concentration of LDL cholesterol, the goals of therapy and individual effect on the therapy. The maximum daily dose for single dose is 80 mg. At the beginning of the treatment and / or during increasing doses every 2-4 weeks is necessary to control the concentration of lipids in blood plasma and adjust the dose. The primary hypercholesterolaemia and combined (mixed) hyperlipidemia For most patients – 10 1 mg once a day; therapeutic effect is apparent within 2 weeks of therapy, and usually reached a maximum within 4 weeks. When dlitelnomlechenii effect persists. Homozygous familial hypercholesterolemia In most cases administered 1 to 80 mg once a day (reduction in the concentration of LDL-C at 18-45%). When liver function deficiency of liver function insufficiency dose should be reduced, with regular checks “liver” transaminases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Renal failure Kidney damage does not affect the concentration of atorvastatin in the blood plasma or the degree of reduction of the concentration-LDL in the treatment of drug, thus the drug dose adjustment is required. Elderly patients are differences in effectiveness, safety and therapeutic effect of the drug in elderly patients compared with the general population has been detected and correction dose is not required (see. The section “Pharmacokinetics”). The use in combination with other drugs. If necessary, the simultaneous application of the cyclosporin dose should not exceed 10 mg per day (see. The section “Special instructions”). Care should be taken to apply, and the lowest effective dose of atorvastatin while the use of HIV protease inhibitors, inhibitors of hepatitis C, clarithromycin and itraconazole.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

OZONE generics

There are no reviews yet.

Add your review